Jason Najum’s work has appeared in many industry-leading publications, covering topics from start-ups to travel and culture. He’s currently a Senior Editor at Psychedelics.com
Latest Article
Rick Doblin Named Time’s Top 100 in Healthcare, Orangutan Uses Medicinal Plant to Heal – Psychedelic News Roundup
In this week’s psychedelic news, Rick Doblin named to Time Magazine’s Top 100, and more.
Edited by: 
Jason Najum
Shulgin Farm Launches Campaign to Preserve Psychedelics History
The famous Shulgin Farm has launched a campaign to honor psychedelic history and expand the community
Written by: Jason Najum
Marijuana Momentum: U.S Government to Reschedule Cannabis
Big news in drug reform policy as the U.S. government will move marijuana from Schedule I to Schedule III.
Written by: Jason Najum
New Study Reviews Side Effects of MDMA Therapy
A new meta-study reviews the side effects of MDMA-assisted psychotherapy across various psychiatric conditions.
Written by: Jason Najum
Ketamine May Reduce Postpartum Depression, Study Finds – Psychedelic News Roundup
In this week’s psychedelic news, a new study shows ketamine helps with postpartum depression, and more.
Edited by: Jason Najum
New Study Shows LSD Microdosing Improves Sleep Duration
A new study found that LSD microdoses led to an increase in sleep duration the night following microdosing.
Edited by: Jason Najum
2024 Psychedelic Conferences & Events
Explore our guide to this year’s top psychedelic conferences and events.
Written by: Jason Najum
Cybin’s Psilocybin Program Granted FDA Breakthrough Designation
FDA support for psychedelics continues as Cybin’s psilocybin program for depression is granted special Breakthrough Designation
Written by: Jason Najum
MindMed Receives FDA Breakthrough Therapy Designation For LSD
Major news in the psychedelic medicine industry as MindMed has received FDA Breakthrough Therapy Designation for its LSD program.
Written by: Jason Najum